Drug Information

Drug General Information
Drug ID
D05RRA
Former ID
DIB013388
Drug Name
HQK-1004
Synonyms
Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 2 [522815]
Company
HemaQuest Pharmaceuticals Inc; Vertex Pharmaceuticals Inc
Canonical SMILES
C(=N)(NCCC[C@@H](C(=O)O)N)N.C(=O)(O)CCC
CAS Number
CAS 80407-72-3
Target and Pathway
Target(s) Thymidine kinase Target Info Modulator [526142]
References
Ref 522815ClinicalTrials.gov (NCT00992732) Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders. U.S. National Institutes of Health.
Ref 526142Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.